Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19

NCT05541510 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

180

Enrollment

INDUSTRY

Sponsor class

Stopped The end of COVID-19 pandemic

Conditions

COVID-19

Interventions

BIOLOGICAL: AD17002 + Formulation buffer
BIOLOGICAL: Placebo

Sponsor

Advagene Biopharma Co. Ltd.

Collaborators

[object Object]